

台灣胰臟醫學會&台灣神經內分泌腫瘤學會
2025 年度年會

日期：2025/12/13 (星期六) 13:30~18:00

地點：集思台中新烏日會議中心 3F 瓦特廳

地址：烏日區高鐵東一路 26 號 3 樓 (高鐵台中站/台鐵新烏日站站內步行 5 分鐘)

主辦單位：台灣胰臟醫學會、台灣神經內分泌腫瘤學會

報名費：會員免費；非會員 1,000 元 (現場繳納)

報到時間：13:15~

Time	Topic	Speaker	Moderator
13:30~13:35	Opening remarks	台灣胰臟醫學會 <u>石宜銘</u> 理事長 台灣神經內分泌腫瘤學會 <u>陳明晃</u> 理事長	
13:35~14:15	台灣本土胃腸道神經內分泌腫瘤 診療共識介紹	<u>黃文冠</u> 醫師 林口長庚 腫瘤科	<u>陳建華</u> 醫師 台北慈濟 胃腸肝膽科
14:15~14:55	Annual Review 2025: Systemic Approaches in the Treatment of NETs	<u>陳明晃</u> 醫師 台北榮總 腫瘤內科	<u>王秀伯</u> 醫師 台大 胃腸肝膽科
14:55~15:35	Challenges and Opportunities in Treating Rare and Aggressive Neuroendocrine Carcinoma	<u>姜乃榕</u> 醫師 台北榮總 腫瘤內科	<u>陳立宗</u> 醫師 高醫附醫 血液腫瘤科
15:35~16:15	Emerging Therapies and Innovations in MCC Management	<u>謝耀宇</u> 醫師 雙和醫院 血液腫瘤科	<u>陳佳宏</u> 醫師 三軍總醫院 腫瘤科
16:15~16:30	Coffee break		
16:30~17:00	The Cutting Edge of EUS in Pancreatic Cancer: From diagnosis to management	<u>廖思嘉</u> 醫師 臺中榮總 胃腸肝膽科	<u>劉乃仁</u> 醫師 林口長庚胃腸肝膽科 <u>楊卿堯</u> 醫師 台大一般外科
CASE 1 : 17:00~17:20 17:20~17:30	病例報告 綜合討論	<u>葉俊杰</u> 醫師 中國附醫 一般外科	<u>葉大森</u> 醫師 林口長庚一般外科 <u>孫灼基</u> 醫師 新光醫院胃腸肝膽科
CASE 2 : 17:30~17:50 17:50~18:00	病例報告 綜合討論	<u>陳怡豪</u> 醫師 台中榮總 一般外科	<u>王心儀</u> 醫師 台北榮總一般外科 <u>陳志仁</u> 醫師 台北馬偕胃腸肝膽科

學會教育積分：(申請中) 台灣外科醫學會、台灣消化系外科醫學會、台灣內視鏡外科醫學會、台灣內科醫學會、台灣消化系醫學會、台灣消化系內視鏡醫學會、中華民國醫用超音波醫學會、中華民國癌症醫學會、中華民國內分泌學會、中華民國核醫學學會

Curriculum Vitae

Name: Wen-Kuan Huang (黃文冠)

Citizenship: Taiwan.

Office Address & Tel No.: 5, Fu-shin st., Kueishan, Taoyuan, Taiwan, 333, R.O.C, 886-3-3281200 ext. 8825; FAX: 886-3-3272236

Education: 1999-2006, MD, School of Medicine, Chung Shan Medical College, Taichung, R.O.C.
2014-2020, PhD, Karolinska Institutet, Department of oncology-pathology, Stockholm, Sweden.

Postgraduate Training:

1. Sep. 2007-Jul. 2010: Residentship, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
2. Jul. 2010-Aug. 2012: Fellowship, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Employment Record:

September 2012-now: Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

September 2021-now: Physician scientist, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

February 2023-now: Assistant professor, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Board Certification:

1. Sep. 14, 2005. Physician board, No.:039891
2. Dec. 07, 2010. Internal Physician board, No.:8626
3. Nov. 2012. Medical Oncology board, NO.:101014

Professional affiliation:

Formosan Medical Association
The Society of Internal Medicine
Taiwan Oncology Society

Research of Interest: cancer metabolism, immune microenvironment, DNA damage repair

Grants

1. CMRPG3B0951 肝膿瘍及反覆化膿性膽道炎與膽道癌的關係及預後 2012/9/1~2013/8/31 (PI)
2. CMRPG3D0521 免疫組織化學染色(IHC)與 DNA 定序對於亞洲族群原發性及轉移性惡性黑色素瘤特定基因 BRAF V600E 突變的比較分析 2014/2/1~2015/1/31 (PI)
3. 103-2314-B-182A-087 – (國科會)探討染色體不穩定作為新標靶治療肢端型黑色素瘤的研究 20140801~20151031 (co-PI)
4. 104-2314-B-182 -009 - (國科會)熊去氧膽酸使用與大腸直腸癌發生的關係：全國性世代研究

20150801~20161031 (co-PI)

5.105-2314-B-182 -025 -MY2 (國科會)癌症病人罹患情感性疾患的發生率、危險因子與死亡風險-全國性研究 20160801~20180731(co-PI)

6.107-2314-B-182 -050 - (國科會)探討前列腺癌病人接受荷爾蒙治療的不良作用 20180801~20190731 (co-PI)

7.108-2314-B-182A-063 - (國科會)微小核糖核酸介導胃腸道基質瘤 imatinib 抗藥性經由調控粒線體代謝研究 2019/08/01~ 2020/07/31 (PI)

8.CMRPG3K172 (二年期) 胃腸道基質瘤 miR-483-3p 調控有氧磷酸化及 imatinib 藥物反應透過抑制琥珀酸脫氫酵素機轉研究 2020/10/1~2022/9/30 (PI)

9.108-2314-B-182A-057- (國科會) 探討雄性激素剝奪治療對於小鼠血管發炎及後續動脈斑塊形成的影響 20190801~ 20221231 (co-PI)

10. 109-2314-B-182 -035-(國科會) 氟尿酸-輔助化療對接受手術治療大腸直腸癌患者的心臟毒性：台灣全國性世代研究 20200801~ 20211031 (co-PI)

11. 111-2314-B-182 -016-(國科會) 糖尿病病人使用 pioglitazone 對日後罹患癌症的風險：從巢式病例對照研究到依時間改變暴露的世代研究 20220801~ 20230731(co-PI)

12.111-2314-B-182A-031- (國科會)胃癌微衛星不穩定狀態與腫瘤免疫微環境特徵分析 2022/08/01 ~2023/07/31 (PI)

13. CMRPG3M2101 TIGIT 抗體結合 PD-1 抗體在微衛星不穩定胃癌療效研究 2022/12/1-2023/11/30 (PI)

14. CMRPG3N0481(三年期) HIF1-alpha 與 circCSPF6/CPSF6 相互作用促進胰腺癌生長 2023/07/01-2026/6/30 (PI)

15. 113-2314-B-182 -028 - (國科會) 建立肝內膽道癌小鼠模型探索免疫微環境與免疫反應標誌物 (PI)

Publications

1.**Huang WK**, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ, Chen SC, Yeh CN, Chen JS, Chen MH, Hsieh CH, Chou WC. Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. *Oncologist*. 2024 Nov 20 (2023):4.8, ONCOLOGY|Q1|70/322 (21.7%)

2. Chen Y, Su Y, Cao X, Siavelis I, Leo IR, Zeng J, Tsagkosis P, Hesla AC, Papakonstantinou A, Liu X, **Huang WK**, Zhao B, Haglund C, Ehnman M, Johansson H, Lin Y, Lehtiö J, Zhang Y, Larsson O, Li X, de Flon FH. Molecular Profiling Defines Three Subtypes of Synovial Sarcoma. *Adv Sci (Weinh)*. 2024 Sep 10. IF (2023):14.3, NANOSCIENCE& NANOTECHNOLOGY |Q1|12/140 (8.5%)

3. **Huang WK**, Zhang Z, Chen J, Lin J, Wang Y, Yan X, Zhang W, Ning S, & You Q. Coordination engineering of FeCo dual single-atom nanozymes with photothermal-enhanced

- cascaded catalysis for efficient pancreatic cancer immunotherapy. *Chemical Engineering Journal*. 2024, Sep; 496, 154203. IF (2023):13.1, ENGINEERING, ENVIRONMENTAL|Q1|3/81 (3.7%)
4. Hung LJ, Huang CY, Tung KC, Chen JS, Huang WK, Hsu CC, Fang YF, Wang CL, Liu PC, Yeh KY, Chang PH, Chang JW, Lin YC, Huang SF, Chou WC. Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohorts. *J Formos Med Assoc*. 2024 Sep 6:S0929-6646(24)00405-4. IF (2023):2.6, MEDICINE, GENERAL & INTERNAL|Q1|70/325 (21.5%)
 5. Chen DY, Chang SH, Huang WK, Hsieh IC, See LC. The cold temperature associated with new-onset heart failure after incorporating dynamic status of multimorbidity: nationwide cohort, Taiwan 2012-2019. *Eur J Prev Cardiol*. 2024 Aug 23:zwae260. IF(2023):8.4, CARDIAC & CARDIOVASCULAR SYSTEMS|Q1|16/220 (7.2%)
 6. Huang WK, Hung YL, Tsai CY, Wu CE, Chou WC, Hsu JT, Yeh TS, Chen JS, Wang SY, Yeh CN. Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. *Am J Cancer Res*. 2024 Jul 15;14(7):3523-3532. IF(2023):3.6, ONCOLOGY|Q2|106/322 (32.9%)
 7. Chen CP, Lin SF, Yeh CN, Huang WK, Pan YR, Hsiao YT, Lo CH, Wu CE. Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations. *Heliyon*. 2024 Mar 30;10(7):e29055. IF(2023):3.4, MULTIDISCIPLINARY SCIENCES|Q1|28/134 (20.8%)
 8. Chang PH, Chen HY, Chang YS, Su PJ, Huang WK, Lin CF, Hsieh JC, Wu CT. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy. *Cancers(Basel)*. 2024 Feb 23;16(5):894. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24.2%)
 9. Yu JH, Li PR, Chen DY, Huang WK, See LC. Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study. *Sci Rep*. 2024 Feb 27;14(1):4771. IF(2023):3.8, MULTIDISCIPLINARY SCIENCES|Q1|25/134 (18.6%)
 10. Chou TT, Hsu HC, Twu CW, Huang WK, Huang HM, Weng SH, Chen MC. Prevalence of Obstructive Sleep Apnea Using Home Sleep Test in Taiwan During the Coronavirus Disease Pandemic. *Nat Sci Sleep*. 2023 Dec 22;15:1107-1116. IF(2023):3.0, NEUROSCIENCES |Q2|140/310
 11. Pan YR, Lai JC, Huang WK, Peng PH, Jung SM, Lin SH, Chen CP, Wu CE, Hung TH, Yu AL, Wu KJ, Yeh CN. PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions. *Cancer Gene Ther*. 2024 Feb;31(2):322-333. IF(2023): 4.8, ONCOLOGY|Q1|70/322 (21.7%)
 12. Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Zinc supplementation decreased incidence of grade ≥ 2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *Eur J Cancer*. 2023 Dec;195:113286. IF(2023):7.6, ONCOLOGY|Q1|38/322 (11.8%)

13. **Huang WK**, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Zinc supplementation decreased incidence of grade ≥ 2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *J Am Acad Dermatol*. 2024 Feb;90(2):368-369. IF(2023):12.8, DERMATOLOGY|Q1|1/94 (1%)
14. Chen DY, Lee CH, Tsai ML, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Tseng CN, Chang SH, Chu PH, Hsieh IC, Wu VC, **Huang WK***. Cancer Therapy-Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. *J Am Heart Assoc*. 2023 Oct 3;12(19):e030447. IF(2023): 5.0, CARDIAC&CARDIOVASCULAR SYSTEMS|Q1|39/220 (17.7%)
15. Yu JH, Hsieh SH, Chen CH, **Huang WK**. Comparison of the safety, effectiveness, and usability of swab robot vs. manual nasopharyngeal specimen collection. *Heliyon*. 2023 Oct 13;9(10):e20757. IF(2023):3.4, MULTIDISCIPLINARY SCIENCES|Q1|28/134 (20.8%)
16. Chen CP, Yeh CN, Pan YR, **Huang WK**, Hsiao YT, Lo CH, Wu CE. Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. *Biomed Pharmacother*. 2023 Oct;166:115389. IF(2023): 6.9, PHARMACOLOGY & PHARMACY|Q1|15/354 (4.2%)
17. Chang JW, Huang CJ, **Huang WK**, Wang YC, Hsieh JJ, Chang YY, Huang YL, Wu CL, Wang YH, Chen SJ, Tan KT, Chen CP, Wu CE. Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. *Clin Transl Immunology*. 2023 Aug 29;12(8):e1465. IF(2023):4.6, IMMUNOLOGY|Q2|56/181 (30.9%)
18. Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, **Huang WK***, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. *Int J Biol Sci*. 2023 May 21;19(9):2772-2786. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
19. Tseng CN, Chen DY, Chang SH, Huang WK, Hsieh MJ, See LC. Ambient Temperature Effect on Acute Myocardial Infarction by Risk Factors: Daily Data From 2000 to 2017, Taiwan. *JACC Asia*. 2023 Mar 14;3(2):228-238.
20. Yeh CN, **Huang WK**, Lu CW, Chen CP, Lin SH, Pan YR, Wu CE. A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction. *Biol Trace Elem Res*. 2023 Dec;201(12):5540-5545.
21. **Huang WK**, Huang SC, Chen CM, Lin PH, Wu CE, Chuang CK, Yeh CN. Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report. *JCO Precis Oncol*. 2023 Jan;7:e2200528. IF(2023): 5.3, ONCOLOGY|Q1|61/322 (18.9%)
22. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, **Huang WK**, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-

resistant prostate cancer. *Int J Cancer*. 2023 Mar 15;152(6):1191-1201. IF(2023): 5.7, ONCOLOGY|Q1|54/322 (16.7%)

23. Pan YR, Wu CE, Huang WK, Chen MH, Lan KH, Yeh CN. Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. *Front Immunol*. 2022 Oct 20;13:982196. IF(2023): 5.7, IMMUNOLOGY|Q1|38/181 (20.9%)

24. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong NSM, Chua DTT, Lee SWM, Chen JS, Yeh CN. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience. *Front Oncol*. 2022 Oct 13;12:1028118. IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

25. Lun R, Roy DC, Hao Y, Deka R, Huang WK, Navi BB, Siegal DM, Ramsay T, Fergusson D, Shorr R, Dowlathshahi D. Incidence of stroke in the first year after diagnosis of cancer-A systematic review and meta-analysis. *Front Neurol*. 2022 Sep 20;13:966190.

26. Huang WK, Ho WP, Hsu HC, Chang SH, Chen DY, Chou WC, Chang PH, Chen JS, Yang TS, See LC. Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer. *Front Cardiovasc Med*. 2022 Aug 3;9:880956. IF(2023): 2.8, CARDIAC&CARDIOVASCULAR SYSTEMS|Q2|79/220 (35%)

27. Huang WK, Wu CE, Wang SY, Chang CF, Chou WC, Chen JS, Yeh CN. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. *Curr Treat Options Oncol*. 2022 Sep;23(9):1303-1319. IF(2023):3.8, ONCOLOGY|Q2|102/322 (31.6%)

27. Wu CE, Chen CP, Huang WK, Pan YR, Aptullahoglu E, Yeh CN, Lunec J. p53 as a biomarker and potential target in gastrointestinal stromal tumors. *Front Oncol*. 2022 Jul 29;12:872202. . IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

28. Chang PH, Lee CH, Wu TM, Yeh KY, Wang HM, Huang WK, Chan SC, Chou WC, Kuan FC, Kuo HC, Kuo YC, Hu CC, Hsieh JC. Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. *Ther Adv Med Oncol*. 2022 Jul 15;14:17588359221110182. IF(2023): 4.3, ONCOLOGY|Q2|88/322 (27.3%)

29. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong NS, Chua DTT, Lee SWM, Chen JS, Yeh CN. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. *Front Oncol*. 2022 Jun 29;12:883399. IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

30. Chen DY, Liu JR, Tseng CN, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Hsieh IC, Chu PH, Chen JS, Wen-Cheng Chang J, Huang WK*, See LC. Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies. *JACC CardioOncol*. 2022 Jun 21;4(2):223-234. IF(2023): 12.0, ONCOLOGY|Q1|22/322 (6.8%)

31. Wang C, Wan H, Zhang H, Yang B, Huang WK, Sun W. Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response. *Front Cell Dev Biol*. 2022 Jun 17;10:915798. IF(2023):4.6, DEVELOPMENTAL BIOLOGY|Q1|5/39 (12.8%)

32. Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E, Carlson J, Huang WK*, Haglund F.

Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. *Front Immunol.* 2022 Jan 7;12:788959. IF(2023): 5.7, IMMUNOLOGY|Q1|38/181 (20.9%)

33. Chen DY, Chen CC, Tseng CN, Chen SW, Chang SH, Huang WK, Wen MS, Hsieh MJ, Hsieh IC. Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study. *EClinicalMedicine.* 2021 Oct 8;41:101149. IF(2023): 9.6, MEDICINE, GENERAL & INTERNAL|Q1|12/325 (3.6%)

34. Jin X, Yan J, Chen C, Chen Y, Huang WK. Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer. *Front Cell Dev Biol.* 2021 Sep 28;9:721505. IF(2023):4.6, DEVELOPMENTAL BIOLOGY|Q1|5/39 (12.8%)

35. Huang WK, Shi H, Akçakaya P, Zeljic K, Gangaev A, Caramuta S, Yeh CN, Bränström R, Larsson C, Lui WO. Imatinib Regulates miR-483-3p and Mitochondrial Respiratory Complexes in Gastrointestinal Stromal Tumors. *Int J Mol Sci.* 2021 Sep 30;22(19):10600. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)

36. Liu CH, Sung PS, Li YR, Huang WK, Lee TW, Huang CC, Lee TH, Chen TH, Wei YC. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. *PLoS Med.* 2021 Jul 19;18(7):e1003707. IF(2023):10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

37. Huang WK, Hsu HC, Chang SH, Chou WC, Chang PH, Chiang SF, Chang JW, Chen JS, Yang TS, See LC. Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis. *Front Pharmacol.* 2021 Jun 29;12:693009. IF(2023): 4.4, PHARMACOLOGY & PHARMACY|Q1|65/354 (18.3%)

38. Wu CE, Huang WK, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy. *Cancers (Basel).* 2021 Jun 23;13(13):3139. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)

39. Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, Tseng CN, Chen SW, Hsieh IC, Chu PH, Lin YC, Hsu CL, Chang JW, Lin MS, Pang JS, Hsieh MJ, Huang WK*. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study. *Prostate.* 2021 Sep;81(12):902-912. IF(2023): 2.7 UROLOGY&NEPHROLOGY|Q2| 36/126 (28.5%)

40. Chang YR, Huang WK, Wang SY, Wu CE, Chen JS, Yeh CN. A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters. *Cancers (Basel).* 2021 May 25;13(11):2587. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)

41. Huang WK, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S. ARHGAP25 Inhibits

Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway. *Int J Biol Sci*. 2021 Apr 24;17(7):1808-1820. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)

42. Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, Chen SW, Chen TH, Chang SH, Hsieh IC, Chu PH, Wen MS, Chen JS, Chang JW, See LC, Huang WK*. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. *JAMA Netw Open*. 2021 Feb 1;4(2):e2036304. IF(2023): 10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

43. Pan YR, Wu CE, Chen MH, Huang WK, Shih HJ, Lan KL, Yeh CN. Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. *Vaccines (Basel)*. 2020 Nov 24;8(4):703. IF(2023): 5.2, MEDICINE, RESEARCH & EXPERIMENTAL|Q1|39/189 (1.5%)

44. Wu CE, Yeh DW, Pan YR, Huang WK, Chen MH, Chang JW, Chen JS, Wang YC, Yeh CN. Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. *Life (Basel)*. 2020 Nov 8;10(11):276.

45. Huang WK, Yeh CN. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. *Biomolecules*. 2020 Sep 30;10(10):1396. IF(2023):4.8, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|67/313 (21.4%)

46. Huang WK, Liu CH, Pang ST, Liu JR, Chang JW, Liaw CC, Hsu CL, Lin YC, See LC. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan. *JAMA Netw Open*. 2020 Aug 3;3(8):e2015189. IF(2023):10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

47. Huang WK, Gao J, Chen Z, Shi H, Yuan J, Cui HL, Yeh CN, Bränström R, Larsson C, Li S, Lui WO. Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor. *Cells*. 2020 May 26;9(6):1333. IF(2023): 5.1, CELL BIOLOGY|Q2|63/205 (30.7%)

48. Huang WK, Chang SH, Hsu HC, Chou WC, Yang TS, Chen JS, Chang JW, Lin YC, Kuo CF, See LC. Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study. *Int J Cancer*. 2020 Oct 1;147(7):1904-1916. IF(2023): 5.7, ONCOLOGY|Q1|54/322 (16.7%)

49. Lee CH, Hsieh JC, Wu TM, Yeh TS, Wang HM, Lin YC, Chen JS, Lee CL, Huang WK, Hung TM, Yen TT, Chan SC, Chou WC, Kuan FC, Hu CC, Chang PH. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. *BMC Cancer*. 2019 Dec 2;19(1):1167. IF(2023):3.4, ONCOLOGY|Q2|110/322 (34.1%)

50. Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, Chuang CK, Chu PH. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. *J Formos Med Assoc*. 2020 Oct;119(10):1461-1475. IF(2023): 2.6, MEDICINE, GENERAL & INTERNAL|Q1|70/325 (21.5%)

51. Chang PH, Wu MH, Liu SY, Wang HM, Huang WK, Liao CT, Yen TC, Ng SH, Chen JS, Lin

- YC, Lin HC, Hsieh JC. The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing. *Cancers (Basel)*. 2019 Apr 15;11(4):540. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)
52. Hou CH, Lee JS, Lin KK, Chang SH, Huang WK, Kuo CF, See LC. Endophthalmitis Incidence of Cancer Patients After Cataract Surgery: A Nationwide Matched Cohort Study in Taiwan. *Am J Ophthalmol*. 2019 Mar;199:246-254. IF(2023):4.1, OPHTHALMOLOGY|Q1| 10/95 (10.5%)
53. Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, Larsson C, Lui WO. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. *Exp Cell Res*. 2018 Oct 1;371(1):287-296. IF(2023):3.3, ONCOLOGY|Q2|118/322 (36.6%)
54. Huang WK, Juang YY, Chung CC, Chang SH, Chang JW, Lin YC, Wang HM, Chang HK, Chen JS, Tsai CS, Yu KH, Kuo CF, See LC. Timing and risk of mood disorders requiring psychotropics in long-term survivors of adult cancers: A nationwide cohort study. *J Affect Disord*. 2018 Aug 15;236:80-87. IF(2023):4.9, PSYCHIATRY|Q1|38/276 (13.7%) IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
55. Chou WC, Wu MH, Chang PH, Hsu HC, Chang GJ, Huang WK, Wu CE, Hsieh JC. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer. *Int J Biol Sci*. 2018 Jan 12;14(2):137-146. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
56. Kao WH, Kuo CF, Chou IJ, See LC, Huang WK, Chiou MJ, Zhang W, Doherty M, Wang CC, Hsu JT, Chen HH, Hong JH. Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study. *Oncotarget*. 2018 Jan 2;9(4):5263-5273.
57. Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang WK*. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study. *J Clin Oncol*. 2017 Nov 10;35(32):3697-3705. IF(2023): 42.1, ONCOLOGY|Q1|6/322 (1.8%)
58. Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, Hsieh CH. Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. *Sci Rep*. 2016 Aug 17;6:31423.
59. Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. *Asia Pac J Clin Oncol*. 2016 Dec;12(4):403-408.
60. Yu KH, Kuo CF, Huang LH, Huang WK, See LC. Cancer Risk in Patients With Inflammatory

Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. *Medicine (Baltimore)*. 2016 May;95(18):e3540.

61. **Huang WK**, Hsu HC, Liu JR, Yang TS, Chen JS, Chang JW, Lin YC, Yu KH, Kuo CF, See LC. The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study. *Medicine (Baltimore)*. 2016 Mar;95(11):e2980.

62. Huang CY, Lu CH, Yang CK, Hsu HC, Kuo YC, **Huang WK**, Chen JS, Lin YC, Chia-Yen H, Shen WC, Chang PH, Yeh KY, Hung YS, Chou WC. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. *Medicine (Baltimore)*. 2015 Nov;94(47):e2135.

63. **Huang WK**, Tu HT, See LC. Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. *Curr Pharm Des*. 2015;21(35):5108-15.

64. Wu CF, Wang HM, **Huang WK**, Chang JW. Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. *Asia Pac J Clin Oncol*. 2015 Dec;11(4):314-8.

68. Lin CY, **Huang WK**, Chung FT, Chang HK. Prognostic factors in cancer patients with symptomatic pituitary metastasis: a clinical case study. *Anticancer Res*. 2015 Feb;35(2):983-7.

69. Wu CE, Wang CW, **Huang WK**, Yang CT, Wu YC, Hou MM, Hsieh CH, Hsieh JJ, Cheng HY, Hsu T, Chang JW. Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection. *Jpn J Clin Oncol*. 2015 Mar;45(3):267-73.

70. **Huang WK**, Kuo YC, Tsang NM, Hsu HC, Shen WC, Chou WC, Yang TS, Chen JS. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. *Anticancer Res*. 2014 Nov;34(11):6755-61.

71. **Huang WK**, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. *Rheumatol Int*. 2014 Oct;34(10):1379-86.

72. **Huang WK**, Lin YC, Chiou MJ, Yang TS, Chang JW, Yu KH, Kuo CF, See LC. Pyogenic liver abscess as a warning sign for primary liver cancer: a nationwide population-based study. *Asian Pac J Cancer Prev*. 2013;14(8):4727-31.

73. **Huang WK**, Chiou MJ, Yu KH, Lin YC, Yang TS, Chen JS, Kuo CF, See LC. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. *Aliment Pharmacol Ther*. 2013 Aug;38(4):432-9.

74. **Huang WK**, Liaw CC, Pang ST, Chuang CK, Chiang YJ, Wu CT, Chang YH, Wang HM, Lin YC, Hsieh JJ, Ou LY, Tsai SI, Yang CH, Yang CT, Chang JW. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital. *Chang Gung Med J*. 2012 Sep-Oct;35(5):402-7.

75. **Huang WK**, Chang JW, See LC, Tu HT, Chen JS, Liaw CC, Lin YC, Yang TS. Higher rate of colorectal cancer among patients with pyogenic liver abscess with *Klebsiella pneumoniae* than those without: an 11-year follow-up study. *Colorectal Dis*. 2012 Dec;14(12):e794-801.

Speaker Profile: Ming-Huang Chen

Current Position


Director, Division of medical oncology, Department of
Oncology, Taipei Veterans General Hospital

Education

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

E-Mail: mhchen9@gmail.com



Biography

Ming Huang-Chen is the Director of the Division of Medical Oncology in the Department of Oncology at Taipei Veterans General Hospital, Taiwan. With over 15 years of extensive clinical experience, he specializes in gastrointestinal tumors (esophageal cancer, gastric cancer, colorectal cancer, biliary tract cancer, and pancreatic cancer), and neuroendocrine tumors. He is also a clinical expert in the application of precision medicine and immunotherapy in cancer treatment. Beyond his clinical practice, Dr. Chen has a wealth of experience in investigator initiated trials (IIT) and publications. He actively contributes to teaching as a professor at National Yang-Ming Chiao-Tung University. He is widely recognized as an oncology precision expert and is frequently invited to share his expertise.

Professional interests and specialties

Clinical Trials and GI cancer

Selected Recent Publications

1. Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP, Chiang NJ, Yeh CN, Hsiao M, Soong J, Su Y, **Chen MH**. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. *Neoplasia*. 2023 Jan; 35: 100856.

2. Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, **Chen MH**, Suksombooncharoen T, Ikeda M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. *Lancet Gastroenterol Hepatol* 2024;29:S2468

3. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, **Chen MH**. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. *Clin Cancer Res*. 2022 Oct 3; 28 (19): 4248-4257.

Current Position

Attending physician, Department of Oncology, Taipei Veterans General Hospital.

Assistant Professor, School of Medicine, National Yang Ming Chiao Tung University.

Adjunct National Institute of Cancer Research, National Health Research Institutes.

Education

M.D. National Defense Medical University, Taipei, Taiwan

Ph.D. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University

E-Mail: njchiang @vghtpe.gov.tw



Biography

Dr. Nai-Jung Chiang is a distinguished oncologist and researcher specializing in the study and treatment of gastrointestinal cancers. With a medical degree from a prestigious university, Dr. Chiang has dedicated their career to advancing cancer research and patient care. She has contributed significantly to the field through numerous research publications in top-tier medical journals. Their work often focuses on the molecular mechanisms of cancer resistance and the development of targeted therapies. They are actively involved in various clinical trials, aiming to bring innovative treatment options to patients.

Professional interests and specialties

Diagnosis and treatment of gastrointestinal malignancies, including esophageal, gastric, biliary tract, and pancreatic cancers.

Expertise in clinical trial design and execution.

Selected Recent Publications

1. Tang CY, Lin YT, Yeh YC, Chung SY, Chang YC, Hung YP, Chen SC, Chen MH, **Chiang NJ**. The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer. Cancer Immunol Immunother. 2025;74(2):41.
2. Chung SY, Yeh YC, Huang CJ, **Chiang NJ**, Dennis Hsu, Chan MH, Lu ML, Hsu TS, Hung YP, Yeh CN, Michael Hsiao, Chang YC, Wang YC, Chen MH. Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma. J Immunother Cancer. 2025;13(1):e010173.
3. Wu WC, Hsu CF, Chen MH, Chen SC, Hung YP, **Chiang NJ**. Incorporating Tumor Genomic Profiling and Circulating Tumor Cell-derived Organoids into Clinical Practice for Gastrointestinal Cancers. Anticancer Res. 2024;44(8):3481-3491.

4. Hsieh CC, Li TW, Li CC, Chen SH, Wei YL, **Chiang NJ***, Shen CH*. DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer. *Oncogenesis*. 2024;13(1):34. (***Co-corresponding author**)
5. Liao BC*, **Chiang NJ***, Chang GC, Su WC, Luo YH, Chong IW, Yang TY, Lai CL, Hsia TC, Ho CL, Lee KY, Hsiao CF, Ku FC, Fang WT, James CH Yang. Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. *JCO Glob Oncol*. 2024;10:e2400125. (***Co-first author**)
6. Cheng SM, Su YY, **Chiang NJ**, Wang CJ, Chao YJ, Huang CJ, Tsai HJ, Chen SH, Chang CY, Tsai CR, Li YJ, Yen CJ, Chuang SC, Jeffrey SM Chang, Shan YS, Hwang DY, Chen LT. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan. *J Biomed Sci*. 2024;31(1):21.
7. Tang CY, Yang SH, Li CP, Su YY, Chiu SC, Bai LY, Shan YS, Chen LT, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, **Chiang NJ***, Chou WC*. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. *Pancreatol*. 2024;24(4):600-607. (***Co-corresponding author**)
8. Chen KA, WM, Eric Chen YT, Ho PK, Chueh CH, Wen YW, Chen MH, **Chiang NJ***, Tsai YW* Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan. *BMC Cancer*. 2024;24(1):622. (***Co-corresponding author**)
9. Su YY*, **Chiang NJ***, Chiu TJ, Huang CJ, Hsu SJ, Lin HC, Yang SH, Yang Y, Chou WC, Chen YY, Bai LY, Li CP, Chen JS. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. *Biomed J*. 2023;31:100696. (***Co-first author**)
10. Chen ZR, Chen-Han Chueh CH, **Chiang NJ***, Tsai YW*. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. *Cost Eff Resour Alloc*. 2023;21(1):61. (***Co-corresponding author**)
11. Su YY, Chao YJ, Wang CJ, Liao TK, Su LJ, Huang CJ, **Chiang NJ**, Yu YT, Tsai HM, Chen LT, Shan YS. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. *Int J Surg*. 2023;109(9):2614-2623.
12. **Chiang NJ**, Chen LT. Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning. *Lancet*. 2023;401(10372):170-171.

廖思嘉簡歷

學歷：

臺北醫學大學醫學系

中國醫藥大學公共衛生研究所流行病學組碩士

專長：

膽胰系統相關的內視鏡超音波及介入性內視鏡超音波、早期癌診斷治療、發炎性腸道疾病(潰瘍性大腸炎&克隆氏症)、消化道出血、慢性肝炎及其併發症

經歷：

臺中榮民總醫院胃腸科主治醫師

臺中榮民總醫院內視鏡中心主任

臺中榮民總醫院內科部住院醫師、總醫師

2016 日本自治大學內視鏡中心 Visiting Faculty

2017 日本北里大學病院消化內科 Visiting Faculty

2018 日本國立癌症研究中心內視鏡中心 Visiting Faculty

2019 日本埼玉大學國際醫療中心內視鏡中心 Visiting Faculty

2024 Asan medical Center 內視鏡中心 Visiting Faculty

2025 Aichi Cancer Center 內視鏡中心 Visiting Faculty

2023-迄今 中興大學講師

Curriculum Vitae

 Chun-Chieh Yeh 葉俊杰	Day of birth	Aug-26-1975
	Gender (Male / Female)	Male
	Academic degree	M.D., Ph.D.
	Affiliation	China Medical University Hospital, Taichung, Taiwan
	Academic title	Associate Professor (Department of Surgery) Attending Physician (General Surgery)
	Specialty	1.Hepatopancreatobiliary surgery 2.Solid organ transplant
	Language Spoken	1.Mandarin 2.English
Excellent Practice		
1.Travel scholar award in ISW 2013		
2.Invited speaker for robotic thyroid surgery in ISOPES 2014		
3.Islet manufacturing 52 cases/2 years (2014-2016)		
4.Oral presentation in IPITA 2015 with topic as “ Factors significantly impacting islet yield from donor pancreata standardized by the North American Donor Score: a retrospective study from the University of Illinois at Chicago islet database”		
5.Oral presentation in TTS2016 with topic entitled as “Robotic simultaneous pancreas kidney transplantation: Case report”		
6.Research grant “ Impact of Manufacturing Procedures on Product Outcome of Human Islets Isolated from Donor Pancreata Standardized by the North American Islet Donor Score” sponsored by Gift of Hope (\$60,000)(2015, finished)		
7.REDCap system programmer for UIC islet manufacturing database setup		
Research target		
1.Improving islet manufacturing in TPIAT (total pancreatectomy with islet autologous transplantation)		
2.Pancreas cancer		
3.Chronic pancreatitis		
4.Liver surgery		

Qualification	Year
1.MD, School of Medicine, Chang-Gung University, Taiwan	1993~2000
2.PhD, Graduate Institute of Clinical Medical Science, China Medical University, Taiwan	2008~2014
3.Da Vinci System training as a console surgeon	2013
4.Transplant fellow in University of Illinois at Chicago	2014-2016
5.Visiting fellow in University of Chicago	2015
Experience	Year
1.Chief of Department of General Surgery, Asian University Hospital, Taichung, Taiwan	2021~now
2.Attending Physician, Department of Surgery, China Medical University Hospital, Taichung, Taiwan	2005~now
3.Training in islet manufacturing with UIC protocol, whole pancreas transplant, robotic pancreas transplant, robotic kidney transplant, small bowel transplant in Department of Transplant surgery at UIC medical center	2014~2016
4.Training of islet manufacturing with CIT protocol in allogeneic islet transplant and autologous islet transplant in University of Chicago	2015.6

Publication within 5 years

(Pancreas field)

1. Huang YK, Cheng WC, Yang JC, Wu YC, Wu HH, Kuo TT, Lo CC, Hsieh CY, Wong SC, Lu CH, Shen CN, Hung MC, Lin JT, **Yeh CC***, Sher YP*. Selective degradation of KRAS protein sensitizes pancreatic cancers to chemotherapy. Nat Cancer. 2024 Mar;5(3):400-419

2. Lin YC, Liao TC, Lin CT, Jeng LB, Yang HR, Hsu CH, Lin WC, Wu CF, **Yeh CC***. Salvage surgeries for splanchnic artery aneurysms after failed endovascular therapy - case series. *Int J Surg*. 2023 Jul 1;109(7):1842-1851.
3. **Yeh CC**, Spaggiari M, Tzvetanov I, Oberholzer J. Robotic pancreas transplantation in a type 1 diabetic patient with morbid obesity: A case report. *Medicine (Baltimore)*. 2017 Feb. 96(6):e5847.
4. **Yeh CC**, Wang LJ, McGarrigle JJ, Wang Y, Liao CC, Omami M, Khan A, Nourmohammadzadeh M, Mendoza-Elias J, McCracken B, Marchese E, Barbaro B, Oberholzer J*. Effect of Manufacturing Procedures on Human Islet Isolation From Donor Pancreata Standardized by the North American Islet Donor Score. *Cell Transplant*. 2017 Jan24. 26(1):33-44
5. Do TT, **Yeh CC**, Wu GW, Hsu CC, Chang HC, Chen HC*. TRIM37 Promotes Pancreatic Cancer Progression through Modulation of Cell Growth, Migration, Invasion, and Tumor Immune Microenvironment. *International Journal Of Molecular Sciences*. 2022 Jan. 23(3):1176 (Co-first author)
6. Chung AK, Lin RT, **Yeh CC**, Yang CY, Wu CJ, Chen PL. Diagnostic rate of germline pathogenic variants in pancreatic ductal adenocarcinoma patients using whole genome sequencing. *Lin JT. Front Genet*. 2023 May10. 14:1172365.
7. Yang CY, Lin RT, Chen CY, **Yeh CC**, Tseng CM, Huang WH, Lee TY, Chu CS, Lin JT. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma. *J Formos Med Assoc*. 2022 Dec. 121(12):2601-2607.
8. Lin RT, Chen PL, Yang CY, **Yeh CC**, Lin CC, Huang WH, Chung AK, Lin JT. Risk factors related to age at diagnosis of pancreatic cancer: a retrospective cohort pilot study. *BMC Gastroenterol*. 2022 May14. 22(1):243
9. Chu CS, Yang CY, **Yeh CC**, Lin RT, Chen CC, Bai LY, Hung MC, Lin CC, Wu CY, Lin JT. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study. *Sci Rep*. 2022 Jan7. 12(1):107.
10. Sung LC, Chang CC, Lin CS, **Yeh CC**, Cherng YG, Chen TL, Liao CC*. Risk of acute atherosclerotic cardiovascular disease in patients with acute and chronic pancreatitis. *Scientific Reports*. 2021 Oct. 11(1):20907-20907
11. Bochenek MA, Veisheh O, Vegas AJ, McGarrigle JJ, Qi M, Marchese E, Omami

- M, Doloff JC, Mendoza-Elias J, Nourmohammadzadeh M, Khan A, **Yeh CC**, Xing Y, Isa D, Ghani S, Li J, Landry C, Bader AR, Olejnik K, Chen M, Hollister-Lock J, Wang Y, Greiner DL, Weir GC, Strand BL, Rokstad AMA, Lacik I, Langer R, Anderson DG*, Oberholzer J. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. *Nature Biomedical Engineering*. 2018 Nov. 2(11):810-821
12. Spaggiari M, Bissing M, Campara M, **Yeh CC**, Tzvetanov I, Jeon H, Benedetti E. Pancreas Transplantation From Pediatric Donors: A United Network for Organ Sharing Registry Analysis. *Transplantation*. 2017 Oct. 101(10):2484-2491
 13. Wong SC, **Yeh CC**, Zhang XY, Hsieh CY, Lo CC, Kuo TT, Lin CC, Chao CH, Liu JP, Chang LC, Wang LH, Sher YP*. Inhibition of CDCP1 by 8-isopentenyl naringenin synergizes with EGFR inhibitors in lung cancer treatment. *Mol Oncol*. 2023 Aug;17(8):1648-1665.

(Liver field)

1. **Yeh CC**, Liao PY, Pandey S, Yang SY, Lai HC, Jeng LB, Chang WC, Ma WL*. Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-clinical Models. *Frontiers in oncology*. 2020 Oct21. 10:572861)
2. **Yeh CC**, Khan A, Muo CH, Yang HR, Li PC, Chang CH, Chen TL, Jeng LB, Liao CC. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan. *Exp Clin Transplant*. 2020 Apr. 18(2):224-233
3. **Chun-Chieh Yeh**, Jaw-Town Lin, Long-Bin Jeng, Hsiu J. Ho, Horng-Ren Yang, Ming-Shiang Wu, Ken N. Kuo, Chun-Ying Wu. Non-steroid Anti-inflammatory Drugs are Associated with Reduced Risk of Early Hepatocellular Carcinoma Recurrence after Curative Liver Resection: A Nationwide Cohort Study. *Ann Surg*. 2015; 261(3):521-6
4. Lai HC, Chung WM, Chang CM, Liao PY, Su YT, **Yeh CC**, Jeng LB, Ma WL*, Chang WC*. Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness. *Anticancer Research*. 2020 Mar. 40(3):1285-1295
5. Lin WC, Chen CC, Westphalen AC, Lin TY, Chang CH, Chen LK, Lin CW, **Yeh CC**, Yu JX, Jeng LB, Chen JH*. Non-Contrast-Enhanced MR Arteriography of

Potential Living-Related Liver Donor: Using Contrast Enhanced CT Arteriography as Standard Reference. Journal Of Magnetic Resonance Imaging. J Magn Reson Imaging. 2023 Sep;58(3):894-904

6. Wu HY, Chang CC, **Yeh CC**, Chen MY, Cherng YG, Chen TL, Liao CC*. Adverse outcomes after non-hepatic surgeries in patients with alcoholic liver diseases: a propensity-score matched study. BMC Gastroenterology. 2022 Nov. 22(1):475-475

CURRICULUM VITAE

Name: Yi-Hao, Chen

Position: Fellow surgeon of General Surgery

Department of Surgery, Taichung Veterans General Hospital

Address: 1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 40705, ROC

Voice : +886-4-23592525 ext. 5021

FAX : +886-4-23581890

E-mail: drblack20@vghtc.gov.tw

Education:

2011 - 2018	Chung Shan Medical University	M.D.
2017 - 2018	Taichung Veterans General Hospital	Intern
2019 - 2020	Taichung Veterans General Hospital	Postgraduate Year
(PGY)		
2020 - 2024	Taichung Veterans General Hospital	Resident , Surgery
2024 - 2025	Taichung Veterans General Hospital	Chief Resident ,
		Surgery
2025 - Present	Taichung Veterans General Hospital	Fellow, Surgery

LICENSES, CERTIFICATION:

2024 Board Certification in Surgery, Taiwan, License Number : 8626

PROFESSIONAL ORGANIZATION

Memberships

2024 - Present Taiwan Association of Surgery

2025 - Present Taiwan Surgical Society of Gastroenterology

PEER REVIEWED PUBLICATIONS

1. Chen YH, Chen IC, Chou CM, Huang SY. Investigating the Association of Polygenic Risk Scores With Thyroid Cancer Susceptibility in a Han Chinese Population. J Endocr Soc. 2024 Mar 16;8(5):bvae052. doi: 10.1210/jendso/bvae052. PMID: 38550279; PMCID: PMC10977953.